Achyut Healthcare BSE Main Board shift: 2026 timeline

What changed: BSE clears migration to the Main Board

Achyut Healthcare Limited has received BSE approval to migrate its equity shares from the SME platform to the BSE Main Board platform. The company said trading on the Main Board is set to begin on January 02, 2026. The move matters because Main Board listing typically places a stock in a broader market ecosystem than the SME platform. It can also change how investors track the company, given the Main Board’s higher visibility. The company linked the migration decision to increasing business activity and brand building.

Company profile and business snapshot

Achyut Healthcare Limited was incorporated in 1996. The company is described as a pharmaceutical trading company dealing in APIs, pharmaceutical products, and medical devices. Separately, the provided company information also states it is involved in manufacturing pharmaceutical formulations in the forms of tablets, capsules, oral liquids, and injectables. These descriptions indicate the company operates across trading and manufacturing-linked activities within pharmaceuticals.

How the migration decision was taken

The Board of Directors, in a meeting held on April 17, 2025, decided to migrate the company’s listing from the BSE SME platform to the BSE Main Board. The stated rationale was “increasing business activities” and “strong brand building.” Shareholders approved the proposal through a postal ballot, with a Postal Ballot Notice dated April 23, 2025. The company then filed its application for migration to the BSE Main Board on July 14, 2025. The later BSE approval completes the key regulatory step needed for the shift.

Trading start date on Main Board: what investors should note

The company indicated that trading on the Main Board will start on January 02, 2026. For investors, this date is the operational milestone, as it marks when trading is expected to occur on the new platform. The announcement does not add further conditions in the provided text, beyond the BSE approval and the stated commencement date.

Corporate actions: stock split and bonus issue details

Achyut Healthcare announced a stock split and bonus issue, aimed at improving liquidity and accessibility. Under the split, each equity share with a face value of ₹10 is subdivided into ten equity shares with a face value of ₹1 each. Following the stock split, the company announced a bonus issue of four bonus shares for every ten shares held (4:10 ratio). The record date for both the stock split and bonus issue is stated as Tuesday, December 10, 2024.

Bonus shares quantum disclosed in company information

During the year under review, the Board of Directors considered and recommended issue of 6,73,02,000 equity shares of ₹1 each as bonus shares. The ratio is stated as 4:10, meaning four new equity shares for every ten existing shares. This disclosure adds scale to the bonus plan beyond the ratio and record date mentioned elsewhere.

Preferential allotment: key terms mentioned

The company also recorded approval for allotment of 58,00,000 equity shares of Re. 1 at a premium of ₹5 per share on a preferential basis. The allotment is stated to be to the Promoter and Non-Promoter group under SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018. The provided text does not include the allotment date or final post-issue shareholding pattern, so those details are not stated here.

Board meeting agenda items and financial results references

One agenda list in the provided text includes considering and approving unaudited financial results for the half year ended September 30, 2024. It also includes a proposal for sub-division of face value (subject to approvals), increase in authorised capital (subject to member approval), and recommending a bonus issue post sub-division. Another reference states: “9 Oct - Board meeting 16 Oct 2025 to approve unaudited H1 results (ended 30 Sep 2025); trading window closed.” These items outline the company’s governance steps around results and corporate actions across different periods.

Market snapshot: price, valuation multiples, and market cap

As per the provided market snapshot, Achyut Healthcare’s share price was ₹7.88 as of July 14, 2026 (04:01 PM closing). At that time, the latest P/E ratio is stated as 788.00, and the latest P/B ratio as 5.42. The market capitalisation is stated at ₹190.19 crore as of the same timestamp. Another snapshot in the provided text lists Market Cap ₹140 crore and Current Price ₹5.93, without a stated date, so it is best read as an earlier reference point rather than a comparable “as of” metric.

Key facts table: dates, actions, and metrics

Company locations and contact details listed

The provided company information includes an address in Ahmedabad, Gujarat (PIN 380058) and another location listed in Hyderabad, Telangana (500032). The Ahmedabad listing includes a telephone number 079-48982691 and email mahendrazenith@hotmail.com. The Hyderabad listing includes telephone numbers 040-67161500, 67162222, 33211000, and additional numbers 040-23420814, 23001153. These details are part of the company’s published contact footprint in the provided text.

Why the sequence matters for investors

The sequence of corporate actions and listing migration provides context on how the company has approached liquidity and market positioning. The split and bonus issue are framed as measures to improve liquidity and accessibility by increasing the number of shares in circulation. The migration to the Main Board is separately linked to higher business activity and brand building. Meanwhile, the disclosures on preferential allotment and board meeting agendas show multiple capital and governance items being processed under SEBI and listing rules.

Conclusion

Achyut Healthcare’s move from the BSE SME platform to the BSE Main Board has a defined operational milestone, with trading expected to start on January 02, 2026. The timeline also includes a ₹10 to ₹1 stock split, a 4:10 bonus issue with record date December 10, 2024, and a disclosed preferential allotment of 58,00,000 shares. Investors tracking the stock will typically watch for exchange notices around the effective trading date and any subsequent corporate disclosures related to these actions.